NCT01607294

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Esperion Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.

Conditions

• Hyperlipidemia
• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	ETC-1002	ETC-1002 Daily for 4 weeks
DRUG	Placebo	Placebo Daily for 4 weeks

Timeline

• Start date: 2012-04-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2012-05-30
• Last updated: 2019-03-29

Locations

1 site across 1 country: United States